LI
LIPO.US Lipella Pharmaceuticals Inc. Common Stock
- Market cap
- USD 2.77K
- P/E
- -
- P/B
- 0.00x
- ROE
- -348.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2025.
Is LIPO.US undervalued?
Graham numberThe Graham number of Lipella Pharmaceuticals Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lipella Pharmaceuticals Inc. Common Stock fundamental analysis
No fundamental analysis for Lipella Pharmaceuticals Inc. Common Stock yet.
Lipella Pharmaceuticals Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lipella Pharmaceuticals Inc. Common Stock
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-vers…
Full company profileLipella Pharmaceuticals Inc. Common Stock financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lipella Pharmaceuticals Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 695K | 962K | 259K | 184K | 450K | 536K | 288M |
| Gross Profit | 11.9K | -14.3K | -1.20M | -2.36M | -2.59M | -3.08M | -3.34M |
| Operating Income | -53.8K | -56.9K | -1.92M | -2.59M | -4.75M | -5.08M | -5.28M |
| EBITDA | 334.00 | -53.7K | -1.86M | -2.59M | -4.61M | -5.01M | -5.18M |
| Net Income | -61.8K | -61.7K | -1.87M | -2.60M | -4.62M | -5.02M | -5.18M |
| EPS | -0.24 | -0.23 | -4.38 | -5.12 | -6.16 | -4.79 | -1.14 |
| Balance Sheet | |||||||
| Total Assets | 119K | 955K | 2.01M | 5.95M | 3.58M | 2.67M | 2.35M |
| Total Liabilities | 237K | 492K | 589K | 1.27M | 433K | 754K | 862K |
| Shareholders' Equity | -118K | 463K | 1.42M | 4.68M | 3.14M | 1.92M | 1.49M |
| Cash & Short-term Investments | 26.0K | 607K | 1.71M | 5.12M | 3.29M | 2.18M | 1.86M |
| Total Debt | 100K | 389K | 283K | 430K | 137K | 47.6K | 264K |
| Cash Flow | |||||||
| Operating Cash Flow | -39.1K | -28.6K | -989K | -1.83M | -3.15M | -3.95M | -3.15B |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 14.4K | 3.00 | 0.00 |
| Free Cash Flow | -39.1K | -28.6K | -989K | -1.83M | -3.16M | -3.95M | -3.15B |
| Ratios | |||||||
| ROE | - | -13.3% | -131.0% | -55.6% | -146.9% | -261.3% | -348.5% |
| ROA | -52.0% | -6.5% | -92.7% | -43.7% | -129.1% | -187.6% | -220.6% |
| Net Profit Margin | -8.9% | -6.4% | -719.3% | -1,410.6% | -1,027.3% | -935.2% | -1.8% |
| Debt to Equity | - | 0.84x | 0.20x | 0.09x | 0.04x | 0.02x | 0.18x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lipella Pharmaceuticals Inc. Common Stock dividends
Lipella Pharmaceuticals Inc. Common Stock has not paid dividends in the last 6 fiscal years.
Last stock split: 1:8 on Nov 8, 2024.
Who owns Lipella Pharmaceuticals Inc. Common Stock
- Insiders 6.31%
- Institutions 0.00%
- Public & others 93.69%
- Shares outstanding 4.62M
- Free float 4.33M
Top funds holding LIPO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 5.78K | 0.13% | 0.00% | May 2025 |
| Vanguard Institutional Extnd Mkt Idx Tr | 4.31K | 0.10% | 0.00% | May 2025 |
| Fidelity Series Total Market Index | 1.34K | 0.03% | 0.00% | May 2025 |
Top institutions holding LIPO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Tower Research Capital LLC | 0.00 | 0.00% | -100.00% | Jun 2025 |
| Mccormack Advisors International | 0.00 | 0.00% | -100.00% | Jun 2025 |
| Virtu Financial LLC | 0.00 | 0.00% | -100.00% | Mar 2025 |
| Bank of America Corp | 0.00 | 0.00% | -100.00% | Jun 2025 |
Lipella Pharmaceuticals Inc. Common Stock company profile
- Company name
- Lipella Pharmaceuticals Inc. Common Stock
- Ticker
- LIPO.US
- Exchange
- USA Stocks
- Listed since
- Dec 19, 2022
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Fiscal year end
- December
- Address
- 7800 Susquehanna St., Pittsburgh, PA, United States, 15208
- Phone
- 412 894 1853
- Website
- lipella.com
About Lipella Pharmaceuticals Inc. Common Stock
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania. On March 30, 2026, Lipella Pharmaceuticals Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Western District of Pennsylvania.
Lipella Pharmaceuticals Inc. Common Stock management
5- Dr. Jonathan Kaufman M.B.A., Ph.D.Co-Founder, Chairman, CEO, President, Secretary & Treasurer · born 1966
- Mr. Douglas Johnston CPAChief Financial Officer · born 1985
- Ms. Michele GruberDirector of Operations
- Ms. Janet OkonskiDirector of Clinical Operations
- Katie JohnstonController